CureVac up as dosing begins in mRNA-based Influenza vaccine candidates study

CureVac NV

08/05/2023 17:53

** U.S.-listed shares of CureVac N.V  CVAC.O  rise 3.6% at
$8.54
    ** Drugmaker reports dosing of first participant in phase 1
part of a study testing Influenza vaccine candidates developed
in collaboration with GSK plc  GSK.L 
    ** The combined early-to-mid-stage study is for multivalent,
modified Influenza vaccine candidates 
    ** The tested multivalent vaccine candidates address all
four WHO-recommended flu strains - CVAC
    ** The trial will access safety, reactogenicity and immune
responses for the mRNA-based vaccine candidates 
    ** CVAC and Britain's GSK have been in an mRNA-focused
partnership since 2020
    ** Including session's gain, U.S.-listed CVAC stock up 41.6%
YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))